{
    "title": "WHO: Nations mulling Gilead's COVID drug should consider trial flop, too",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8873199/WHO-says-advice-remdesivir-3-4-weeks.html",
    "date": "2020-10-23",
    "keywords": [
        "drug",
        "trial",
        "remdesivir",
        "covid19",
        "john",
        "miller",
        "health",
        "evidence",
        "week",
        "fda",
        "study",
        "solidarity",
        "treatment",
        "gilead",
        "whos",
        "nebehay",
        "swaminathan",
        "disease",
        "release",
        "world",
        "group",
        "science",
        "incs",
        "medicine",
        "light",
        "top",
        "soumya",
        "news",
        "conference",
        "food",
        "administration",
        "decision",
        "impact",
        "approval",
        "institute",
        "allergy",
        "risk",
        "death",
        "survival",
        "benefit",
        "statement",
        "japan",
        "arab",
        "union",
        "supply",
        "move",
        "note",
        "addition",
        "arm",
        "control",
        "possibility",
        "bias",
        "september",
        "topline",
        "draft",
        "manuscript",
        "publication",
        "company",
        "time",
        "friday",
        "use",
        "agency",
        "panel",
        "effectiveness",
        "janet",
        "official",
        "care",
        "diaz",
        "pandemic",
        "approach",
        "transparent",
        "way",
        "stephanie",
        "michael",
        "reporting",
        "deena",
        "beasley",
        "peter",
        "graff",
        "editing",
        "kevin",
        "liffey",
        "richard",
        "chang"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}